For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Therapeutic Intervention | Cisplatin, Starting dose 30 mg/m2 Dose level -1 20 mg/m2; Irinotecan, Starting Dose 50 mg/m2, Dose level -1 40 mg/m2 | None | None | 27 | 40 | 0 | 40 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Abdominal distention | None | Gastrointestinal disorders | None | View |
| Abdominal pain | None | Gastrointestinal disorders | None | View |
| Anorexia | None | Metabolism and nutrition disorders | None | View |
| Aspiration pneumonia | None | Respiratory, thoracic and mediastinal disorders | None | View |
| Chills | None | General disorders | None | View |
| Cholelithiasis | None | Hepatobiliary disorders | None | View |
| Creatinine increased | None | Investigations | None | View |
| Dehydration | None | Metabolism and nutrition disorders | None | View |
| Depressed level of consciouness | None | Nervous system disorders | None | View |
| Diarrhea | None | Gastrointestinal disorders | None | View |
| Dysphagia - esophageal (related to radiation) | None | Gastrointestinal disorders | None | View |
| Dysphagia, esophagitis, odynophagai | None | Gastrointestinal disorders | None | View |
| Facial cellulitis | None | Infections and infestations | None | View |
| Fatigue | None | General disorders | None | View |
| Febrile neutropenia | None | Blood and lymphatic system disorders | None | View |
| Fever | None | General disorders | None | View |
| Headache | None | Nervous system disorders | None | View |
| Hemoglobin decreased | None | Investigations | None | View |
| Hyponatremia | None | Metabolism and nutrition disorders | None | View |
| Hypotension | None | Vascular disorders | None | View |
| Illeus | None | Gastrointestinal disorders | None | View |
| Infected gastrocutaneous fistula | None | Gastrointestinal disorders | None | View |
| Leukocytes (WBC 1.3) | None | Investigations | None | View |
| Muscle weakness | None | Musculoskeletal and connective tissue disorders | None | View |
| Nausea | None | Gastrointestinal disorders | None | View |
| Neutrophil count decreased | None | Investigations | None | View |
| Platelet count decreased | None | Investigations | None | View |
| Pneumonitis | None | Respiratory, thoracic and mediastinal disorders | None | View |
| Post-nasal drip | None | General disorders | None | View |
| Right shoulder pain | None | Musculoskeletal and connective tissue disorders | None | View |
| Small bowel obstruction | None | Gastrointestinal disorders | None | View |
| Subacute fx of L1 vertebral body | None | Musculoskeletal and connective tissue disorders | None | View |
| Thromboembolism | None | Vascular disorders | None | View |
| Urosepsis | None | Infections and infestations | None | View |
| Vomiting | None | Gastrointestinal disorders | None | View |
| Weakness | None | General disorders | None | View |
| White blood cell decrease | None | Investigations | None | View |